ROYALDAY COMPANY LIMITED: GLP-1 import refusal records
Has FDA refused imports of GLP-1 products from ROYALDAY COMPANY LIMITED?
Yes. FDA’s import refusal records list 2 refused shipment lines declared as made by ROYALDAY COMPANY LIMITED (Hong Kong) whose FDA product code names semaglutide, from Jan 27, 2026 to Jan 28, 2026. None of them carries a product code that FDA’s Import Alert 66-80 lists as a GLP-1 API or powder form.
- Country
- Hong Kong
- City in FDA records
- Tsim Sha Tsui
- FEI numbers on the lines
- 3017931401
- Refused lines
- 2
- Lines with an Import Alert 66-80 API or powder code
- 0
- Drugs named in the product codes
- Semaglutide
- Refusal dates
- Jan 27, 2026 to Jan 28, 2026
The declared manufacturer is the firm named on the import entry. A refusal is FDA’s decision on one shipment line; it is not a finding about the firm’s other products.
Import Alert 66-80’s Green List (published Oct 9, 2026) prints a redaction in place of every firm name, so this index cannot say whether ROYALDAY COMPANY LIMITED is on it.
Refused shipment lines
| FDA refusal charges | Shipment ID | ||||
|---|---|---|---|---|---|
| Jan 28, 2026 | Hong Kong | 61PDL72 SEMAGLUTIDE (ANTI-DIABETIC) | Code not listed on Import Alert 66-80 | FALSE: The article is subject to refusal of admission pursuant to Section 801(a)(3) of the FD&C Act in that it appears to be misbranded within the meaning of Section 403(a)(1 ) of the FD&C Act in that the labeling is false or misleading in any particular. NUTRIT LBL: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be misbranded in that the label or labeling fails to bear the required nutrition information. | SCS-1989210-3/14/1 |
| Jan 27, 2026 | Hong Kong | 61PDL72 SEMAGLUTIDE (ANTI-DIABETIC) | Code not listed on Import Alert 66-80 | FALSE: The article is subject to refusal of admission pursuant to Section 801(a)(3) of the FD&C Act in that it appears to be misbranded within the meaning of Section 403(a)(1 ) of the FD&C Act in that the labeling is false or misleading in any particular. NUTRIT LBL: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be misbranded in that the label or labeling fails to bear the required nutrition information. | SCS-1806600-6/14/1 |
FDA refusal charges on these lines
A line can carry several charges. Text is FDA’s charge statement, verbatim.
| FALSE: The article is subject to refusal of admission pursuant to Section 801(a)(3) of the FD&C Act in that it appears to be misbranded within the meaning of Section 403(a)(1 ) of the FD&C Act in that the labeling is false or misleading in any particular. | 2 |
| NUTRIT LBL: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be misbranded in that the label or labeling fails to bear the required nutrition information. | 2 |
This page lists public regulatory records as published by the issuing agency. A record is not a finding by this site. A warning letter states the agency’s view at the time it was issued; companies may have responded or corrected the issue since. Follow each link for the original document and any close-out letter. Report an error or add a company response.
Sources
Records last pulled Nov 15, 2026. Every entry links to the original public record.
2 lines from FDA files read Nov 15, 2026.